Structured population data were available for 6 of 6 supporting studies. 6 studies described participants with type 2 diabetes. 6 studies described adult participants.

2 relevant studies have unresolved authoritative design evidence and do not contribute to design-specific or RoB-specific claims.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, unknown_unresolved, usual_care.

4 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Dapagliflozin 10 mg

Core clinician-reference fields are available or not applicable.

Patients received a fixed-dose combination of dapagliflozin and gliclazide for 16 weeks.

FDC of Dapagliflozin 10 mg + Gliclazide SR 60 mg

Patients in the test arm received FDC of dapagliflozin 10 mg and gliclazide 60 mg SR tablets, while those in the reference arm received dapagliflozin 10 mg, given orally every day for 16 weeks of the treatment period.

Patients received dapagliflozin 10 mg monotherapy for 16 weeks.

Patients in the reference arm received dapagliflozin 10 mg, given orally every day for 16 weeks of the treatment period.

Authoritative quality diagnostic: invalid or missing unit.

Dapagliflozin and Gliclazide Combination Improves Glycemic Control

Not extracted from the authoritative source.

Not applicable to this study design or comparison.

Available source content was suppressed because validation identified a conflict.

Clinician-reference record is usable with limitations in: arms, risk_of_bias.

Authoritative quality diagnostic: rob tool design incompatible.

Dapagliflozin may improve RAAS markers in diabetes patients

Source evidence could not be resolved sufficiently for this field.

Clinician-reference record is usable with limitations in: design, risk_of_bias.

Patients with newly diagnosed T2DM treated with Dapagliflozin for 3 months.

Dapagliflozin Treatment

All patients were treated with Dapagliflozin 10 mg/day, primary and secondary endpoints were assessed by cardiorenal markers (albumin-to creatinine ratio (ACR) and calculated glomerular filtration rate (GFR)), metabolic marker (HbA1c), Anthropometric parameters (BMI and blood pressure), were measured at baseline and follow-up.

Authoritative quality diagnostic: sample size arm total mismatch.

Authoritative quality diagnostic: source evidence unresolved.

Dapagliflozin improves kidney function in early T2DM

Vit E group

Patients receiving dapagliflozin for 24 weeks.

Dapa group

The Dapa group received 5 mg/day of dapagliflozin post-breakfast (with an optional increase to 10 mg, as determined by the attending physician), while the Vit E group received 150 mg/day of tocopherol acetate (50 mg three times daily post-meal). Both groups continued the daily medication for 24 weeks.

Patients receiving vitamin E for 24 weeks.

Dapagliflozin improves metabolic outcomes in type 2 diabetes patients

Clinician-reference record is usable with limitations in: design, arms, risk_of_bias.

Dapagliflozin-linagliptin combo improves glycemic control and organ protection

Loose combination (LC) arm

Participants received one tablet containing dapagliflozin 10 mg and pioglitazone 15 mg, administered orally once daily in the morning.

Fixed-dose combination (FDC) arm

Participants were randomized in a 1:1 ratio to receive one of the two study treatments for 12 weeks, in addition to their background metformin regimen. FDC arm One tablet containing dapagliflozin 10 mg and pioglitazone 15 mg, administered orally once daily in the morning.

Participants received the same agents administered separately as an add-on therapy to stable metformin.

Participants were randomized in a 1:1 ratio to receive one of the two study treatments for 12 weeks, in addition to their background metformin regimen. LC arm: same agents administered separately.

Dapagliflozin × HbA1c

Available supporting studies

Dapagliflozin and Gliclazide Combination Improves Glycemic Control

Dapagliflozin may improve RAAS markers in diabetes patients

Dapagliflozin improves kidney function in early T2DM

Dapagliflozin improves metabolic outcomes in type 2 diabetes patients

Dapagliflozin-linagliptin combo improves glycemic control and organ protection

Dapagliflozin-pioglitazone combo improves glycemic control in type 2 diabetes